RxSight (RXST, Financials) shares dropped 43.6% to $14.74 as of 10:28 a.m. ET on Thursday after the company cut its full-year ...

Q1 2025 Management View CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors ...

Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, for patients ...

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket on Thursday after the ...

RxSight faces revenue decline and rising competition in the IOL market. Click here to find out why I am neutral on RXST stock ...

NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of ...

Phakic IOL technologies have undergone substantial improvements in recent years, with progressive upgrades in design and material and more accurate sizing strategies.At the ESCRS winter meeting, Erik ...

Bausch + Lomb has recalled intraocular lenses in response to a growing number of reports that some patients are experiencing inflammatory reactions in their eyes, the company said Thursday.

Bausch + Lomb has initiated a voluntary recall of its enVista platform intraocular lenses (IOLs) following reports of TASS.

Cataract extraction with intraocular lens insertion is associated with reduced odds of falls and major injuries in older ...

Bausch + Lomb has recalled its intraocular lenses after receiving reports of cases inflammation. The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular ...